Status:
COMPLETED
Combined Therapy for Hepatocellular Carcinoma >3-<5 cm
Lead Sponsor:
Zagazig University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization (cTACE) + microwave ablation (MWA) versus only TACE or MWA for tre...
Detailed Description
This study aims to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization (cTACE)+microwave ablation (MWA) versus only TACE or MWA for treatment of hepat...
Eligibility Criteria
Inclusion
- Solitary HCC \>3-\<5 cm
- Absence of extra-hepatic metastases
- Absence of a history of encephalopathy or refractory ascites
- Child-Pugh class A or B cirrhosis.
Exclusion
- Poor patient compliance
- Child-Pugh class C cirrhosis
- Severe coagulation disorders
- Portal vein thrombosis
- Renal impairment (6) previous local ablation therapy of HCC
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 20 2020
Estimated Enrollment :
278 Patients enrolled
Trial Details
Trial ID
NCT04721470
Start Date
January 1 2017
End Date
October 20 2020
Last Update
January 22 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.